Last reviewed · How we verify
Vinblastine/prednisone
Vinblastine/prednisone is a Vinca alkaloid and corticosteroid Small molecule drug developed by Baylor College of Medicine. It is currently in Phase 3 development for Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Testicular cancer, Hodgkin's disease. Also known as: Velban/Deltasone.
Vinblastine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, thereby inducing cell cycle arrest at the metaphase and apoptosis. Prednisone is a corticosteroid that has anti-inflammatory and immunosuppressive properties.
Vinblastine is used in combination with other treatments, including prednisone, to study various types of lymphoma in clinical trials. The exact mechanism of action of vinblastine is not specified in the provided information, but it is listed as an intervention in trials for lymphoma conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vinblastine/prednisone |
|---|---|
| Also known as | Velban/Deltasone |
| Sponsor | Baylor College of Medicine |
| Drug class | Vinca alkaloid and corticosteroid |
| Target | Microtubules and glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vinblastine works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Prednisone, on the other hand, has anti-inflammatory and immunosuppressive effects, which can help to reduce inflammation and prevent the immune system from attacking the body's own tissues.
Approved indications
- Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Testicular cancer, Hodgkin's disease
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Infection
- Steroid-induced psychosis
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (NA)
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (PHASE2)
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (PHASE2)
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma (PHASE2)
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma (PHASE2)
- Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) (PHASE3)
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinblastine/prednisone CI brief — competitive landscape report
- Vinblastine/prednisone updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI
Frequently asked questions about Vinblastine/prednisone
What is Vinblastine/prednisone?
How does Vinblastine/prednisone work?
What is Vinblastine/prednisone used for?
Who makes Vinblastine/prednisone?
Is Vinblastine/prednisone also known as anything else?
What drug class is Vinblastine/prednisone in?
What development phase is Vinblastine/prednisone in?
What are the side effects of Vinblastine/prednisone?
What does Vinblastine/prednisone target?
Related
- Drug class: All Vinca alkaloid and corticosteroid drugs
- Target: All drugs targeting Microtubules and glucocorticoid receptor
- Manufacturer: Baylor College of Medicine — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Testicular cancer, Hodgkin's disease
- Also known as: Velban/Deltasone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing